Pharmacists in Uniondale, NY Accepting Medicare
18 Pharmacists found. Showing 1 - 18
 Mr. Anthony James Defranco, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 546 Uniondale Ave, Uniondale, NY 11553 Phone: 516-486-4333 Fax: 516-486-0464 |
Dr. Andrew Thomas Lorenzo, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1123 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-505-1230 |
 Kristine Marie Hinners, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 603 Uniondale Ave, Uniondale, NY 11553 Phone: 516-481-4825 |
Eva Zhang Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 51 Charles Lindbergh Blvd, Uniondale, NY 11553 Phone: 516-536-0800 |
Jaya Ghingoor Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 603 Uniondale Ave, Uniondale, NY 11553 Phone: 516-481-4825 |
Mr. Robert E Marin, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1153 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-505-1230 Fax: 516-505-1235 |
Dr. Gisela Yamilet Canales, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 261 Manor Pkwy, Uniondale, NY 11553 Phone: 516-859-5162 |
Dr. Michael Vincent Ercolano, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 875 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-539-9834 |
Mrs. Afra H Khan, B.PHARM Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1121 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-292-0622 Fax: 516-292-0662 |
Dexter Thomas, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 51 Charles Lindbergh Blvd, Uniondale, NY 11553 Phone: 516-536-0800 |
Mrs. Natasha Yasmin Haq Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 603 Uniondale Ave, Uniondale, NY 11553 Phone: 516-481-4825 |
Shibu G Tharakan Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 603 Uniondale Ave, Uniondale, NY 11553 Phone: 516-481-4825 Fax: 516-483-4185 |
Mr. Donald James Cantalino, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 546 Uniondale Ave, Uniondale, NY 11553 Phone: 516-486-4333 Fax: 516-486-0464 |
Mrs. Marjan Hadi Sojeri, B.S. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1123 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-505-1230 |
Dr. Hiral Shah, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 603 Uniondale Ave, Uniondale, NY 11553 Phone: 516-481-4825 Fax: 516-481-4185 |
Ms. Nicole Charmaine Hoke, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 603 Uniondale Ave, Uniondale, NY 11553 Phone: 516-481-4825 Fax: 516-483-4185 |
Dr. Diana Mary Mohan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1123 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-505-1508 |
Dr. Mariella Francesca Scozzari, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1123 Jerusalem Ave, Uniondale, NY 11553 Phone: 516-505-1230 |
News Archive
Study finds disease management programs improve the quality of health care
Disease management programs that help guide the care of patients with chronic health problems appear to improve the quality of health care, but there is little evidence that such efforts actually save money, according to a study issued by the RAND Corporation.
FDA: New drug Tivicay approved to treat HIV-1 infection
The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.
New data shows EXPAREL provides effective pain control following total knee arthroplasty
Pacira Pharmaceuticals, Inc. today announced results of an independent, physician-initiated study designed to evaluate the difference in postsurgical pain and opioid consumption between patients who received EXPAREL versus a multi-drug analgesic cocktail for pain management following total knee arthroplasty (TKA).
Pfizer announces tasocitinib Phase 2 data for plaque psoriasis
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
› Verified 8 days ago
Pharmacists
Clinical Social Workers
Dentists
Counselors
Occupational Therapists
Psychologists